A new Treg play­er emerges with $46M and back­ing from Take­da

In re­cent years, the cho­rus of biotechs and Big Phar­ma back­ers tar­get­ing reg­u­la­to­ry T cells — al­so known as “Tregs” — for can­cer and au­toim­mune dis­eases has on­ly grown loud­er.

The newest voice is from Egle Ther­a­peu­tics, which sang out a $46.4 mil­lion Se­ries A round on Fri­day led by LSP and Bpifrance through their In­no­Bio 2 fund. Take­da’s ven­ture arm al­so chipped in, about a year af­ter the phar­ma struck a re­search pact with the Paris-based up­start.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER